About
Altido Therapeutics is a clinical-stage biotechnology company developing a novel CAR-TEAM T cell-based immunotherapy platform that genetically engineers a patient’s T cells to attack difficult-to-treat solid tumors such as glioblastoma by targeting multiple tumor antigens simultaneously.
Explore Altido Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.